Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

NCT05283226 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma
Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: NRC-2694-A
DRUG: Paclitaxel

Sponsor

NATCO Pharma Ltd.